Multivalent influenza vaccines
AssigneeSanofi
InventorsTim ALEFANTIS, Sudha CHIVUKULA
Life of this patent
Estimating the term…
Abstract
Provided are octavalent influenza vaccine compositions comprising eight mRNA, each mRNA comprising an open reading frame encoding a different influenza antigen. Also provided are lipid nanoparticles (LNPs) for delivering said mRNA.
Claims42
An influenza vaccine composition, comprising eight messenger RNA (mRNA), each mRNA comprising an open reading frame (ORF) encoding a different influenza antigen.
5-7. (canceled)
(canceled)
14-18. (canceled)
(canceled)
22-24. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of eliciting an immune response in a subject in need thereof, comprising administering to the subject, optionally intramuscularly, intranasally, intravenously, subcutaneously, or intradermally, a prophylactically effective amount of an influenza vaccine composition comprising eight messenger RNA (mRNA), each mRNA comprising an open reading frame (ORF) encoding a different influenza antigen.
(canceled)
46-49. (canceled)
An influenza vaccine composition, comprising eight messenger RNA (mRNA), each mRNA comprising an open reading frame (ORF) encoding a different influenza antigen,
- wherein the mRNA is formulated in a lipid nanoparticle (LNP),
- wherein the LNP comprises:
- a cationic lipid selected from the group consisting of OF-02, cKK-E10, GL-HEPES-E3-E10-DS-3-E18-1, GL-HEPES-E3-E12-DS-4-E10, and GL-HEPES-E3-E12-DS-3-E14, at a molar ratio of 35% to 55%;
- a polyethylene glycol (PEG) conjugated (PEGylated) lipid at a molar ratio of 0.25% to 2.75%;
- a cholesterol-based lipid at a molar ratio of 20% to 45%;
- and
- a helper lipid at a molar ratio of 5% to 35%,
- wherein all of the molar ratios are relative to the total lipid content of the LNP.
An influenza vaccine composition, comprising eight messenger RNA (mRNA), each mRNA comprising an open reading frame (ORF) encoding a different influenza antigen,
- wherein the composition comprises one mRNA encoding an H3 HA antigen, one mRNA encoding an N2 NA antigen, one mRNA encoding an H1 HA antigen, one mRNA encoding an N1 NA antigen, one mRNA encoding an HA antigen from the Influenza B/Yamagata lineage, one mRNA encoding an NA antigen from the Influenza B/Yamagata lineage, one mRNA encoding an HA antigen from the Influenza B/Victoria lineage, and one mRNA encoding an NA antigen from the Influenza B/Victoria lineage.
Dependencies are inferred from the claim text.